Paraneoplastic autoimmune hypophysitis: An emerging concept
- PMID: 34876362
- DOI: 10.1016/j.beem.2021.101601
Paraneoplastic autoimmune hypophysitis: An emerging concept
Abstract
Pituitary autoimmunity is one of the principal causes of hypopituitarism. Additionally, hypophysitis is one of the immune-related adverse events associated with immunotherapy. Recent case-oriented research has revealed a novel type of autoimmune hypophysitis, anti-PIT-1 hypophysitis, related to isolated adrenocorticotropic hormone (ACTH) deficiency and immune checkpoint inhibitor-related hypophysitis, as a form of paraneoplastic syndrome. Under these conditions, the ectopic expression of pituitary antigens present in tumors evokes a breakdown of immune tolerance, resulting in the production of autoantibodies and autoreactive cytotoxic T cells that specifically harm pituitary cells. Consequently, an innovative clinical entity of paraneoplastic autoimmune hypophysitis has been purported. This novel concept and its underlying mechanisms provide clues for understanding the pathogenesis of autoimmune pituitary diseases and can be applied to other autoimmune diseases. This review discusses the etiology of paraneoplastic autoimmune hypophysitis and its future.
Keywords: anti-PIT-1 hypophysitis; immune-checkpoint inhibitor-related hypophysitis; isolated ACTH deficiency; paraneoplastic syndrome.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest Y.T. has been an advisory board member and consultant for Novo Nordisk, Versartis, and Ascendis Pharma and accepted a research grant from Novo Nordisk and Ono Pharmaceutical.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
